Antibe Therapeutics Inc.
1063 King St. West
Suite 210
Hamilton
Ontario
L8S 4S3
Canada
Tel: 905-515-6132
Fax: 905-528-9862
Website: http://www.antibe-therapeutics.com/
204 articles about Antibe Therapeutics Inc.
-
Antibe Provides Update on CCAA Proceedings
4/19/2024
Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE) announced that the Company sought an extension of its previously announced stay of proceedings (“ Stay ”) under the Companies’ Creditors Arrangement Act (the “ CCAA ”) at a hearing before the Ontario Superior Court of Justice (Commercial List) (the “ Court ”) on April 18, 2024.
-
Antibe Announces TSX Delisting Review
4/16/2024
Antibe Therapeutics Inc. announced that the Toronto Stock Exchange is reviewing the eligibility for continued listing on the TSX of the securities of the Company.
-
Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act
4/9/2024
Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE, OTCQX: ATBPF) announced that it intends to file an application today with the Ontario Superior Court of Justice (Commercial List) (the " Court ") for an Initial Order under the Companies' Creditors Arrangement Act (the " CCAA ").
-
Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
4/1/2024
Antibe Therapeutics Inc. announced that it received verbal notice on the afternoon of March 28, 2024 from the U.S. Food and Drug Administration that otenaproxesul has been placed on clinical hold, postponing the initiation of the planned Phase II trial.
-
Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting
3/20/2024
Antibe Therapeutics Inc. is pleased to announce a moderated poster presentation of data from otenaproxesul’s recent pharmacokinetic/pharmacodynamic (“PK/PD”) study.
-
Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting
3/7/2024
Antibe Therapeutics Inc. is pleased to announce a poster presentation of data from otenaproxesul’s recent pharmacokinetic/pharmacodynamic (“PK/PD”) study.
-
Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma
3/4/2024
Antibe Therapeutics Inc. announced that the arbitrator has found in favor of Nuance Pharma in the dispute regarding the license agreement for the commercialization of otenaproxesul in the Greater China region.
-
Antibe Reports Q3 2024 Interim Financial and Operating Results
2/14/2024
Antibe Therapeutics Inc. has filed its financial and operating results for the fiscal quarter ended December 31, 2023.
-
Antibe Extends Early Warrant Exercise Incentive Program
2/1/2024
Antibe Therapeutics Inc. is extending the Early Warrant Exercise Incentive Program for its 6.4 million outstanding and unlisted share purchase warrants having an exercise price of $1.50 and expiring on July 31, 2024.
-
Antibe Announces Early Warrant Exercise Incentive Program - December 29, 2023
12/29/2023
Antibe Therapeutics Inc. is pleased to announce an Early Warrant Exercise Incentive Program for its 6.5 million outstanding and unlisted share purchase warrants having an exercise price of $1.50 and expiring on July 31, 2024.
-
Antibe Reports Q2 2024 Interim Financial and Operating Results
11/13/2023
Antibe Therapeutics Inc., a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, has filed its financial and operating results for the fiscal quarter ended September 30, 2023.
-
Antibe Reports PK Results of First Clinical Study of Otenaproxesul’s New Formulation
11/9/2023
Antibe Therapeutics Inc. is pleased to announce the PK results of the pharmacokinetic/pharmacodynamic study of otenaproxesul’s faster-absorbing formulation.
-
Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation
11/1/2023
Antibe Therapeutics Inc. is pleased to announce the completion of the pharmacokinetic/pharmacodynamic (“PK/PD”) study of otenaproxesul’s faster-absorbing formulation for acute pain.
-
Antibe Initiates First Clinical Study of Otenaproxesul’s New Formulation
10/18/2023
Antibe Therapeutics Inc. is pleased to announce the initiation of the pharmacokinetic/pharmacodynamic (“PK/PD”) study of otenaproxesul’s faster-absorbing formulation for acute pain.
-
Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul
9/28/2023
Antibe Therapeutics Inc., a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies targeting pain and inflammation, is pleased to announce Health Canada’s approval to initiate the pharmacokinetic/pharmacodynamic study of otenaproxesul’s faster-absorbing formulation for acute pain.
-
Antibe Announces Results of 2023 Annual Meeting
9/8/2023
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier today.
-
Antibe Reports Q1 2024 Interim Financial and Operating Results
8/14/2023
Antibe Therapeutics Inc. has filed its financial and operating results for the fiscal quarter ended June 30, 2023.
-
Antibe Reports 2023 Year-End Results and Business Highlights
6/29/2023
Antibe Therapeutics Inc. has filed its financial and operating results for the fiscal year ended March 31, 2023.
-
Antibe’s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials Summit
4/25/2023
Antibe Therapeutics Inc. today announced its participation in the Precision in Clinical Trials Summit being held in Boston on May 1 – 2, 2023.
-
Antibe to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
4/18/2023
Antibe Therapeutics Inc. today announced its participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference being held in person on April 25-26, 2023.